Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and other skincare treatments in its portfolio. More: With
read more
Preliminary phase 4 data highlights improvements in sleep, work productivity and quality of life More: Fezolinetant shows real-world promise for menopause symptoms Source: News
read moreJohnson & Johnson is taking flight with the New York Jets, joining the NFL team’s roster in a multiyear agreement as its official medical innovation sponsor. More: J&J and the Jets: Pharma signs on as NFL team's medical innovation sponsor
read moreMerck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the end of 2028,” a company spokesperson confirmed to Fierce Pharma. The decision follows a strategic review of the products made at the site, which prompted
read moreModerna is backing the American Lung Association’s call for people with lung diseases to get vaccinated for the upcoming respiratory virus season. More: Moderna-backed ALA campaign takes a shot at boosting respiratory vaccine uptake Source: fierce
read moreNovartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta. More: Novartis sues AZ’s Alexion over ‘false and misleading’ Ultomiris marketing Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals